DRMA — Dermata Therapeutics Share News
0.000.00%
Last trade - 00:00NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million
Brief: Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing
Brief: Dermata Therapeutics Announces Strategic Pivot To OTC Skin Care - SEC Filing
Dermata Therapeutics Q3 net loss narrows as R&D expenses fall
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy
U.S. STOCKS ON THE MOVE-Waldencast, Danaher, Asset Entities
Dermata Therapeutics climbs on acne product shift
Brief: Dermata Withdraws FDA Application for Xyngari, Shifts Focus to OTC Skin Care
Brief: Dermata Therapeutics Inc - Potential NDA Filing For Xyngari In H1 2028 - SEC Filing
Brief: Dermata Therapeutics Inc - Announces Topline Results From Phase 3 Trial Of Xyngari - SEC Filing
U.S. STOCKS ON THE MOVE-Ultragenyx Pharma, Winnebago, Par Pacific
U.S. STOCKS ON THE MOVE-Rigel Pharma, Concentrix, Avis Budget
U.S. STOCKS ON THE MOVE-Lockheed Martin, New Fortress Energy, Northrop Grumman
Dermata Therapeutics rises after positive late-stage study data of acne treatment